Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LCL161 |
Synonyms | |
Therapy Description |
LCL161 is a SMAC mimetic that inhibits Inhibitor of Apoptosis Protein (IAP) family proteins, potentially leading to increased tumor cell death (PMID: 21681929, PMID: 24976294, PMID: 25113756). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LCL161 | LCL-161|LCL 161 | SMAC Mimetic 8 | LCL161 is a SMAC mimetic that inhibits Inhibitor of Apoptosis Protein (IAP) family proteins, potentially leading to increased tumor cell death (PMID: 21681929, PMID: 24976294, PMID: 25113756). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02098161 | Phase II | LCL161 | LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis | Completed | USA | 0 |